Bone Disease in Elderly Individuals With CKD

Advances in Chronic Kidney Disease

Volumn 17, Issue 4, 2010, Pages

  Kansal, Sheru ^a   Fried, Linda ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bone mineral density; Chronic kidney disease; Osteoperosis; Renal osteodystrophy

Indexed keywords

25 HYDROXYVITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PARATHYROID HORMONE[1-34]; RALOXIFENE; VITAMIN D;

BONE DENSITY; BONE DISEASE; BONE REMODELING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIALYSIS; FRACTURE; GERIATRIC PATIENT; HUMAN; KIDNEY FUNCTION; MINERAL METABOLISM; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DISEASES; CHRONIC DISEASE; FRACTURES, BONE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; OSTEOPOROSIS; RENAL DIALYSIS;

EID: 77953695773     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.05.001     Document Type: Review

References (79)

1. Moe S., Druke T., Cunningham J., et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69 (2006) 1945-1953
2. Consensus Development Conference. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94 (1993) 646
3. Hadjidaki D.J., and Androulakis I.I. Bone remodeling. Ann N Y Acad Sci 1092 (2006) 385-396
4. Berger C., Langsetmo L., Joseph L., et al. Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ 178 (2008) 1660-1668
5. Sipos W., Pietschmann P., Rauner M., et al. Pathophysiology of osteoporosis. Wien Med Wochenschr 159 (2009) 230-234
6. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 8 (1996) 1043-1051
7. Siddiqui N.A., Shetty K.R., and Duthie Jr. E.H. Osteoporosis in older men: Discovering when and how to treat it. Geriatrics 54 (1999) 20-22, 27-28
8. Farmer M.E., White L.R., Brody J.A., et al. Race and sex differences in hip fracture incidence. Am J Public Health 74 (1984) 1374-1380
9. Center J.R., Nguyen T.V., Schneider D., et al. Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 353 (1999) 878-882
10. Falahati-Nini A., Riggs B.L., Atkinson E.J., et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106 (2000) 1553-1560
11. Ongphiphadhanakul B., Rajatanavin R., Chanprasertyothin S., et al. Serum estradiol and estrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol 49 (1998) 803-809
12. Orwoll E.S., and Klein R.F. Osteoporosis in men. Endocr Rev 16 (1995) 87-116
13. Harper K.D., and Weber T.J. Secondary osteoporosis. Diagnostic considerations. Endocrinol Metab Clin North Am 27 (1998) 325-348
14. Liu S., Gupta A., and Quarles L.D. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 16 (2007) 329-335
15. Silver J., and Levi R. Cellular and molecular mechanisms of secondary hyperparathyroidism. Clin Nephrol 63 (2005) 119-126
16. Rodriguez M., Felsenfeld A.J., and Llach F. Calcemic response to parathyroid hormone in renal failure: Role of calcitriol and the effect of parathyroidectomy. Kidney Int 40 (1991) 1063-1068
17. Levin A., Bakris G.L., Molitch M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71 (2007) 31-38
18. Clase C.M., Kiberd B.A., and Garg A.X. Relationship between glomerular filtration rate and the prevalence of metabolic abnormalities: Results from the Third National Health and Nutrition Examination Survey (NHANES III). Nephron Clin Pract 105 (2007) c178-c184
19. Vassalotti J.A., Uribarri J., Chen S.C., et al. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 51 4 Suppl 2 (2008) S56-S68
20. Murray T.M., Rao L.G., Divieti P., et al. Parathyroid hormone secretion and action: Evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr Rev 26 (2005) 78-113
21. Lehmann G., Ott U., Kaemmerer D., et al. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3-5. Clin Nephrol 70 (2008) 296-305
22. Moosgaard B., Christensen S.E., Vetsergaard P., et al. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol 68 (2008) 707-715
23. Tsurusaki K., Ito M., and Hayashi K. Differential effects of menopause and metabolic disease on trabecular and cortical bone assessed by peripheral quantitative computed tomography (pQCT). Br J Radiol 73 (2000) 14-22
24. Sit D., Kadiroglu A.K., Kayabasi H., et al. Relationship between bone mineral density and biochemical markers of bone turnover in hemodialysis patients. Adv Ther 24 (2007) 987-995
25. Ambrus C, Almasi C, Berta K, et al: Bone mineral density and parathyroid function in patients on maintenance hemodialysis. Int Urol Nephrol (in press)
26. Andress D.L. Adynamic bone in patients with chronic kidney disease. Kidney Int 73 (2008) 1345-1354
27. Moe S.M., Drueke T.B., Block G.A., et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113 (2009) S1-S130
28. Pei Y., Hercz G., Greenwood C., et al. Risk factors for renal osteodystrophy: A multivariant analysis. J Bone Miner Res 10 (1995) 149-156
29. Thalassinos N.C., Hadjiyanni P., Tzanela M., et al. Calcium metabolism in diabetes mellitus: Effect of improved blood glucose control. Diabet Med 10 (1993) 341-344
30. Alikhani M., Alikhani Z., Boyd C., et al. Advanced glycation end-products stimulate osteoblastic apoptosis via MAP kinase and cytosolic apoptotic pathways. Bone 40 (2007) 345-353
31. Almedia M., Han L., Martin-Millan M., et al. Skeletal involution by age-associated oxidative stress and it's acceleration by loss of sex steroids. J Biol Chem 282 (2007) 27285-27297
32. Lima E.M., Goodman W.G., Kuizon B.D., et al. Bone density measurements in pediatric patients with renal osteodystrophy. Pediatr Nephrol 18 (2003) 554-559
33. Klawansky S., Komaroff E., Cavanaugh P.F., et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14 (2003) 570-576
34. Hsu C.Y., Cummings S.R., McCulloch C.E., et al. Bone mineral density is not diminished by mild-moderate renal insufficiency. Kidney Int 61 (2002) 1814-1820
35. Fried L.F., Shlipak M.G., Stehman-Breen C., et al. Kidney function predicts the rate of bone loss in older individuals: The Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci 61 (2006) 743-748
36. Mittalhenkle A., Gillen D.L., and Stehman-Breen C.O. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 44 (2004) 672-679
37. Ioannidis G., Papaioannou A., Hopman W.M., et al. Relation between fractures and mortality: Results from the Canadian Multicentre Osteoporosis Study. CMAJ 181 (2009) 265-271
38. van Staa T.P., Dennison E.M., Leufkens H.G., et al. Epidemiology of fractures in England and Wales. Bone 29 (2001) 517-522
39. Kanis J.A., Borgstrom F., De Laet C., et al. Assessment of fracture risk. Osteoporos Int 16 (2005) 581-589
40. Holroyd C., Cooper C., and Dennison E. Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab 22 (2008) 671-685
41. Alem A.M., Sherrard D.J., Gillen D.L., et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58 (2000) 396-399
42. Piraino B., Chen T., Cooperstein L., et al. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 30 (1988) 57-62
43. Araújo S.M., Ambrosoni P., Lobão R.R., et al. The renal osteodystrophy pattern in Brazil and Uruguay: An overview. Kidney Int 63 Suppl 85 (2003) S54-S56
44. Gerakis A., Hadjidakis D., Kokkinakis E., et al. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 13 (2000) 437-443
45. Atsumi K., Kushida K., Yamazaki K., et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J of Kidney Dis 33 (1999) 287-293
46. Coco M., and Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36 (2000) 1115-1121
47. Block G.A., Klassen P.S., Lazarus J.M., et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 (2004) 2208-2218
48. Danese M.D., Kim J., Doan Q.V., et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47 (2006) 149-156
49. Jadoul M., Albert J.M., Akiba T., et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int 70 (2006) 1358-1366
50. Mitterbauer C., Kramar R., and Oberbauer R. Age and sex are sufficient for predicting fractures occurring within 1 year of hemodialysis treatment. Bone 40 (2006) 516-521
51. Ensrud K.E., Lui L.Y., Taylor B.C., et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167 (2007) 133-139
52. Dawson-Hughes B. National Osteoporosis Foundation Guide Committee: A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 93 (2008) 2463-2465
53. Kanis J.A., Johnell O., Oden A., et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19 (2008) 385-397
54. Nickolas T.L., Leonard M.B., and Shane E. Chronic kidney disease and bone fracture: A growing concern. Kidney Int 74 (2008) 721-731
55. Jamal S.A., Hayden J.A., and Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: A meta-analysis. Am J Kidney Dis 49 (2007) 674-681
56. Ammann P., and Rizzoli R. Bone strength and its determinants. Osteoporos Int 14 Suppl 3 (2003) S13-S18
57. The National Osteoporosis Foundation Clinician's Guide to Prevention and Treatment of Osteoporosis. Available at. http://www.nof.org/professionals/NOF_Clinicians_Guide.htm
58. Baim S., Binkley N., Bilezikian J.P., et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 11 (2008) 75-91
59. Hodgson S.F., Watts N.B., Bilezikian J.P., et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9 (2003) 544
60. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services (3rd ed). Available at: www.ahrq.gov/clinic/uspstfix.htm
61. Jamal S.A., Gilbert J., Gordon C., et al. Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 21 (2006) 543-548
62. Hourigan S.R., Nitz J.C., Brauer S.G., et al. Positive effects of exercise on falls and fracture risk in osteopenic women. Osteoporos Int 19 (2008) 1077-1086
63. Kemmler W., von Stengel S., Engelke K., et al. Exercise effects on bone mineral density, falls, coronary risk factors, and health care costs in older women: The randomized controlled Senior Fitness and Prevention (SEFIP) Study. Arch Intern Med 170 (2010) 179-185
64. Yamazaki S., Ichimura S., Iwamoto J., et al. Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Metab 22 (2004) 500-508
65. Ubara Y., Tagami T., Nakanishi S., et al. Significance of minimodeling in dialysis patients with a dynamic bone disease. Kidney Int 68 (2005) 833-839
66. MacLaughlin J., and Holick M.F. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 76 (1985) 1536-1538
67. Jackson R.D., LaCroix A.Z., Gass M., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354 (2006) 669-683
68. Kooienga L., Fried L., Scragg R., et al. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in CKD. Am J Kidney Dis 53 (2009) 408-416
69. Ghazali A., Fardellone P., Pruna A., et al. Is low plasma 25-(OH) vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?. Kidney Int 55 (1999) 2169-2177
70. Wolf M., Shah A., Gutierrez O., et al. Vitamin D levels and early mortality in incident hemodialysis patient. Kidney Int 72 (2007) 1004-1013
71. Josephson M.A., Schumm L.P., Chiu M.Y., et al. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation 78 (2004) 1233-1236
72. Cueto-Manzano A.M., Konel S., Freemont A.J., et al. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis 35 (2000) 227-236
73. Saab G., Young D.O., Gincherman Y., et al. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 105 (2007) c132-c138
74. Jamal S.A., Bauer D.C., Ensrud K.E., et al. Alendronate treatment in women with normal to severely impaired renal function: An analysis of the Fracture Intervention Trial. J Bone Miner Res 22 (2007) 503-508
75. Miller P.D., Roux C., Boonen S., et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res 20 (2005) 2105-2015
76. Ishani A., Blackwell T., Jamal S.A., et al. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 19 (2008) 1430-1438
77. Miller P.D., Schwartz E.N., Chen P., et al. Teriparatide in postmenopausal women with osteoporosis and impaired renal function. Osteoporos Int 18 (2007) 59-68
78. Amerling R, Harbord N, Winchester JF, et al: Bisphosphonate use in chronic kidney disease associated with adynamic bone disease. Abstract from the ISN Nexus Symposium on the Bone and the Kidney; October 12-15, 2006; Copenhagen, Denmark
79. Hernández E., Valera R., Alonzo E., et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 63 (2003) 2269-2274